Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Carl Zeiss Meditec : ZEISS PLEX Elite 2.0 at ARVO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2019 | 08:51am EDT

ZEISS Launches First Dual-Speed Swept-Source OCT/OCTA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

The ZEISS PLEX Elite 2.0 is a dual-speed Swept-Source Optical Coherence Tomographer that provides expanded visualization options on how diseases are manifesting in patients

ZEISS Medical Technology Segment today launched the first dual-speed Swept-Source OCT/OCTA that will now scan at 200kHz, in addition to 100kHz, providing doctors a deeper and more detailed view into the retina enabling visualization options for various diseases. The fPLEX Elite 2.0 enables faster, deeper, and higher resolution imaging of the eye, elevating ophthalmic imaging and clinical research to a new level. Varying speeds can be applied to different disease states in the eye and expand possibilities of research.

'The launch of PLEX Elite 2.0 is a major step forward in the evolution of Swept-Source OCT/OCTA,' said Jim Mazzo, Global President of Ophthalmic Devices at Carl Zeiss Meditec. 'It is another example of our continued commitment to clinical research and building technology to benefit patients.'

At the core of this accelerated development of research with PLEX Elite is the Advanced Imaging Network, a unique collaboration of practitioners with the mission of advancing research and innovation in the fields of retina and glaucoma. This one-of-a-kind innovation engine brings together renowned clinicians and scientists from around the world using a cloud-based software platform to interact and collaborate in real time, all with a unified goal to advance the future of eye care.

With the PLEX Elite 2.0's deeper and more detailed view into the retina, doctors can fully image conditions such as posterior staphylomas, retinal detachments, high myopia, and choroidal tumors. This evolution provides faster scans to visualize from the retinal vitreous interface all the way down to the choroid to assess highly curved myopic eyes in an unprecedented way.

'Collaboration with leading experts continues to be at the heart of our innovation process,' said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. 'This new level of collaboration has the potential to open new frontiers of discovery in research, and to accelerate the development of innovations to benefit patients today and in the future.'

Since its launch in 2016, the Advanced Imaging Network has grown significantly and expanded beyond the retina to glaucoma and optic nerve diseases and promises to expand further. The network plans to continue their collaboration and enable researchers to further experiment on the clinical utility of Swept Source technology in Ophthalmology.

During ARVO, ZEISS will also showcase the PLEX Elite along with the company's other flagship devices at Booth 1317. For more information, visit fhttps://www.zeiss.com/meditec/int/c/zeiss-at-arvo-2019.html.

Ultra HD Spotlight of a Myopic Staphyloma with a 6mm B-scan depth acquired at 200kHz enabling clinicians to fully image and assess highly curved retina. Courtesy of Professor Jean-Francois Korobelnik. fImage Download

SS-OCT HD Angiography 12x12mm image showing a Branch Retinal Vein Occlusion scanned at 200kHz. This single scan allows clinicians to see deeper, wider, and in higher resolution revealing more detailed microvasculature. Courtesy of Dr. Roger Goldberg. fImage Download

Sebastian Frericks

Director Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220-116

hinvestors.meditec@zeiss.com

Laurie Ferguson

Head of Global Communications Ophthalmic Devices

Phone: +1 925 719 7825

Email: hpress.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,050 employees worldwide, the Group generated revenue of EUR1,280.9m in fiscal year 2017/18 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For more information visit our website at: fwww.zeiss.com/med

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARL ZEISS MEDITEC AG
08/12CARL ZEISS MEDITEC : continues strong growth trend after nine months of 2018/19
AQ
08/09EUROPE : Italy leads European shares lower on political uncertainty
RE
08/09GLOBAL MARKETS LIVE : Bayer, Huawei, Airbus, Occidental Petroleum…
08/09CARL ZEISS MEDITEC : continues strong growth trend after nine months of 2018/19
EQ
08/02CARL ZEISS MEDITEC AG : Preliminary announcement of the publication of quarterly..
EQ
07/16INFORMATION PURSUANT : Carl Zeiss Meditec is aiming for the upper end of its rev..
PU
07/15CARL ZEISS MEDITEC : is aiming for the upper end of its revenue forecast for the..
EQ
06/19EUROPE : European stocks tread water, all eyes on Fed
RE
06/18A pivotal month of June
06/04A war on all fronts
More news
Financials (EUR)
Sales 2019 1 428 M
EBIT 2019 264 M
Net income 2019 167 M
Finance 2019 659 M
Yield 2019 0,64%
P/E ratio 2019 54,2x
P/E ratio 2020 46,6x
EV / Sales2019 5,84x
EV / Sales2020 5,34x
Capitalization 8 998 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 85,89  €
Last Close Price 101,90  €
Spread / Highest target -1,86%
Spread / Average Target -15,7%
Spread / Lowest Target -46,0%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG47.29%9 979
THERMO FISHER SCIENTIFIC24.90%110 607
DANAHER CORPORATION35.83%100 482
BOSTON SCIENTIFIC CORPORATION20.94%59 201
INTUITIVE SURGICAL3.95%57 377
EDWARDS LIFESCIENCES CORPORATION45.26%46 171